17 / 24
Is 2
nd-
Line Treatment a Reality?
Phase III Clinical Trials
•
Nal-IRI-based chemotherapy
NAPOLI-1: 5-FU + nal-IRI
•
Oxaliplatin-based chemotherapy (conflicting results)
CONKO-004 (-): OFF vs 5-FU/LV
PANCREOX (+): FOLFOX vs 5-FU/LV
Controversies
Different regimes used
Oxaliplatin dose reduction: 10% with OFF and 45% with FOLFOX
CONKO-003 progression during first-line, PANCREOX within four weeks after first-
line